(August 18, 2025, Shanghai, China）— On August 18, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) announced that its self-developed innovative drug Luvometinib Tablets(Chinese trade name:复迈宁^®; the “Drug”) has gained Breakthrough Therapy Designation by the Saudi Food and Drug Authority(SFDA) for the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms. This milestone marks the acceleration of the Drug’s registration and commercialization process in Saudi Arabia.

Recently, Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with GeneQuantum Healthcare (Suzhou) Co., Ltd. ("GeneQuantum"). As agreed, Henlius will obtain the development and exclusive commercialization rights for the innovative HER2-targeted antibody-drug conjugate (ADC) GQ1005 in China and certain overseas markets. The drug candidate, currently in phase 3 clinical development, is being evaluated for HER2-positive breast cancer.

Shanghai, China, August 13, 2025 – Henlius (2696.HK) announced that the New Drug Application (NDA) for the HLX04-O, a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the company and Essex, for the treatment of wet (neovascular) age-related macular degeneration(wAMD) has been accepted by the Center for Drug Evaluation of the National Medical Products Administration (NMPA). As of now, none of the bevacizumab products marketed in Chinese mainland has been approved for the treatment of wAMD.

On August 13, 2025 (Pacific Time), the World Conference on Lung Cancer (WCLC) 2025 has officially unveiled the list of accepted abstracts. Ten studies on Henlius' innovative PD-L1 ADC HLX43, anti-EGFR mAb HLX07 and anti–PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab) have been selected for multiple sessions, including oral presentations, poster tours, and poster presentations. Among these, 4 will be featured as oral presentations and 2 as poster tours. The selected studies span first-line treatment for non-squamous non–small cell lung cancer (nsNSCLC), squamous non–small cell lung cancer (sqNSCLC), and extensive-stage small cell lung cancer (ES-SCLC). In addition, innovative therapies are being actively promoted to explore the therapeutic potential of immunotherapy in a wide range of populations, including the perioperative setting for patients with NSCLC and patients with brain metastases.

(August 11, 2025, Shanghai, China) On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc. (Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. Fosun Pharma will retain the rights to develop, manufacture, and commercialize XH-S004 in Chinese Mainland, Hong Kong SAR and Macau SAR.

HO CHI MINH CITY, Vietnam, August 7, 2025 -- Club Med, the pioneer in premium all-inclusive holidays for 75 years, and PT Grahatama Kreasi baru (GKB), a leading Indonesian hospitality developer, announced the signing of a Hotel Management Agreement that heralds the highly anticipated Club Med Manado in North Sulawesi, adding another jewel to the East and Southeast Asia region portfolio.

Recently, Shanghai Henlius Biotech, Inc. (2696.HK) announced that HLX43 for Injection, the company’s innovative programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate (ADC) has been approved by the United States Food and Drug Administration (FDA) to initiate a phase 1 clinical trial incorporating thymic carcinoma (TC) cohort to benefit a broader range of tumor patients globally. Previously, HLX43 has already been approved to conduct phase 2 MRCT in patients with advanced non-small cell lung cancer (NSCLC) in China, U.S., Japan and Australia. To date, no PD-L1 targeting ADC has been approved for marketing globally. HLX43 is the first PD-L1 ADC progressed to phase 2 clinical trial development globally.

On 3 August, the Shede Aged Baijiu Festival global tour was staged in Kuala Lumpur, Malaysia, under the theme “Sharing Shede Wisdom with the World”. Shede Spirits warmly invited distinguish guests from various sectors to gather in Kuala Lumpur, a city renowned for its rich Chinese cultural heritage, to share Shede’s wisdom, foster cultural exchange, and explore the internationalization of Chinese baijiu.

Shanghai, China, July 31, 2025 — Henlius (2696.HK) today announced that the company’s independently developed and manufactured anti-PD-1 monoclonal antibody, serplulimab (trade name in Europe: Hetronifly^®), has completed its first shipment to the Indian market. This milestone marks the official entry of this innovative therapy developed in China into the world’s most populous country, further addressing the urgent clinical needs in the treatment of small cell lung cancer (SCLC). Serplulimab is the world’s first anti-PD-1 therapy approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) and has been approved in nearly 40 countries and regions including China, the United Kingdom, Germany, India, Indonesia, and Singapore, reaching close to half of the global population.